Key clinical point: Long-term data point to the efficacy and safety of chemotherapy-free, first-line treatment of indolent lymphoma.
Major finding: After a median of 10.6 years’ follow up, 73% of patients were alive, and 36% did not require chemotherapy.
Study details: Ten-year follow-up data from two trials on 321 previously untreated patients who had follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, or indolent lymphoma not otherwise specified.
Disclosures: The study was funded in part by the Stockholm County Council and by the Nordic Lymphoma Group. The trials analyzed in the study were supported by Roche. Dr. Lockmer reported having no financial disclosures. Her coauthors reported relationships with Novartis, Gilead, Roche, and Takeda, among others.
Lockmer S et al. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262.
This Week's Must Reads
Gene sequencing sheds light on outcomes in MPN, Grinfeld J et al. N Engl J Med. 2018;379:1416-30
Phase 2 trial evaluates entospletinib in DLBCL, Burke JM et al. Clin Lymphoma Myeloma Leuk. 2018 Aug;18(8):e327-e331
Obesity lowers risk of death in PE patients, Khan Z et al. CHEST. 2018 Oct. doi: 10.1016/j.chest.2018.08.919
DOACs perform well in real-world AF study, ESC CONGRESS 2018
T cell infusion effective in PML, Muftuoglu M et al. N Engl J Med. 2018 Oct 11;379:1443-51
Must Reads in Indolent Lymphoma
Throly system predicts thromboprophylaxis in lymphoma patients, Leukemia and Lymphoma 2018, Dubrovnik, Croatia
Long-term data on chemo-free approach in advanced indolent lymphoma, Lockmer S et al. J Clin Oncol. 2018 Oct 4:JCO1800262. doi: 10.1200/JCO.18.00262
Race and pruritus create cancer risk picture, Kwatra SG et al. J Am Acad Dermatol. 2018 Sep 11. doi: 10.1016/j.jaad.2018.08.044.
Watchful waiting in follicular lymphoma, Davies GA et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 28. doi: 10.1016/j.clml.2018.08.015
RELEVANCE data sheds light on follicular lymphoma treatment, Morschhauser F et al. N Engl J Med. 2018;379:934-47.